At least  weeks or  half-lives, whichever is shorter, must have elapsed after prior chemotherapy or small molecule targeted therapy
Any other systemic or regional anticancer therapy (cytotoxic chemotherapy, embolization) within  weeks or  cycle length, whichever is shorter, prior to first day of study treatment (for treatment phase)
Major surgery, radiotherapy, chemotherapy, or other anti-neoplastic therapy (including prednisone ?  mg/day or equivalent) within  days or  half-lives (whichever is shorter) prior to Cycle , Day  treatment.
Last dose of prior anti-tumor therapy < days prior to the first administration of idasanutlin or < times terminal half-life of that therapy, whichever is shorter
Targeted therapy, including monoclonal antibodies and immuno-oncology therapies:  weeks or  half-lives, whichever is shortest
Hormonal therapy:  weeks or  half-lives, whichever is shortest
Experimental therapy:  weeks or  half-lives, whichever is shortest
The disease should be progressing/relapsed during or after the previous treatment. At least  weeks should have elapsed since prior chemotherapy or  half-lives, whichever is shorter, as long as the patient recovered from any related toxicities to ? Grade .
Must have received at least one line of chemotherapy and no other standard therapy with proven clinical benefit is available. At least  weeks should have Elapsed since prior chemotherapy or  half-lives, whichever is shorter, as long as the patient recovered from acute toxicity of previous therapies to ? grade .
The disease should be progressing/relapsed during or after the previous treatment. At least  weeks should have elapsed since prior chemotherapy or  half-lives, whichever is shorter, as long as the patient recovered from acute toxicity of previous therapies to ? Grade .
At least  weeks or  half-lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis, except for systemic inhibitory/stimulatory immune checkpoint therapy, which requires  half-lives\r\n* Exceptions:\r\n** There is no time restriction with regard to prior intrathecal chemotherapy (including [incl.] steroids) provided there is complete recovery from any acute toxic effects of such\r\n** Subjects receiving hydroxyurea may be enrolled provided there has been no increase in dose for at least  weeks prior to starting apheresis\r\n** Subjects who are on standard ALL maintenance type chemotherapy (vincristine, -mercaptopurine or oral methotrexate) may be enrolled provided that chemotherapy is discontinued at least  week prior to apheresis\r\n** Subjects receiving steroid therapy at physiologic replacement doses (=<  mg/day of prednisone or equivalent doses of other corticosteroids) only are allowed provided there has been no increase in dose for at least  weeks prior to starting apheresis\r\n** For radiation therapy: radiation therapy must have been completed at least  weeks prior to enrollment, with the exception that there is no time restriction if the volume of bone marrow treated is less than % and also the subject has measurable/evaluable disease outside the radiation port
Anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within  weeks or  half lives, whichever is shorter, prior to initiation of study treatment
If patient received any previous systemic therapy, the last dose must have been ?  days prior to randomization (or ?  half-lives of that drug - whichever is shorter) with all clinically significant therapy- related toxicities having resolved to less than or equal to Grade 
Prior antineoplastic antibody therapy within  half-lives or  week prior to apheresis, whichever is greater
Patients must have completed any chemotherapy, radiation therapy, surgery, or biologic therapy >=  weeks (or >=  half-lives, whichever is shorter) prior to entering the study; patients must be >=  weeks since any prior administration of a study drug in an exploratory investigational new drug (IND)/phase  study or >=  week from palliative radiation therapy; patients must have recovered to eligibility levels from prior toxicity or adverse events
Have discontinued all previous cancer therapies (except nonsteroidal aromatase inhibitors for participants in Part B), and any agents that have not received regulatory approval for any indication, for at least  days or  half lives prior to study enrollment, whichever is shorter, and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy for at least  days
Patient receiving anticancer therapy (e.g. chemotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization) ? weeks or  half-lives (whichever is shorter) prior to CD,
At least  weeks or  half-lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis, except for systemic inhibitory/stimulatory immune checkpoint therapy, which requires  half-lives\r\n* Exceptions:\r\n** There is no time restriction with regard to prior intrathecal chemotherapy (including [incl.] steroids) provided there is complete recovery from any acute toxic effects\r\n** Subjects receiving hydroxyurea may be enrolled provided there has been no increase in dose for at least  weeks prior to starting apheresis\r\n** Subjects who are on standard ALL maintenance type chemotherapy (vincristine, -mercaptopurine or oral methotrexate) may be enrolled provided that chemotherapy is discontinued at least  week prior to apheresis\r\n** Subjects receiving steroid therapy at physiologic replacement doses (>=  mg/day of prednisone or equivalent doses of other corticosteroids) only are allowed provided there has been no increase in dose for at least  weeks prior to starting apheresis\r\n** For radiation therapy: Radiation therapy must have been completed at least  weeks prior to enrollment, with the exception that there is no time restriction if the volume of bone marrow treated is less than % and also the subject has measurable/evaluable disease outside the radiation port
Current or prior use of anticancer therapy before TIL collection:\r\n* Chemotherapy within the past  weeks\r\n* Tyrosine kinase inhibitor (TKI) within the past  week\r\n* Investigational therapy within the past  weeks or  half-lives, whichever is shorter
(For cohort A only): Time from prior therapy: a. Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter. Hormonal therapy is not considered anti-neoplastic therapy. b. Radiotherapy: wide-field radiotherapy (e.g. > % of marrow-bearing bones) completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment
At least  weeks from previous cytotoxic chemotherapy or radiation therapy and at least  half-lives or  weeks, whichever is shorter, after targeted or biologic therapy excepting prior treatment with CTLA , PD-, or PD-L blocking antibodies for which only a  week interval is required. Patients with prostate cancer, unless orchiectomy has been performed in them, may continue to receive androgen deprivation therapy (ADT), anti-androgen therapy or therapy that interferes with androgenic stimulation.
Having received cancer-directed therapy (chemotherapy, radiotherapy, hormonal therapy, biologic or immunotherapy, etc) or an investigational drug within  weeks ( weeks for mitomycin C and nitrosoureas) or  half-lives of that agent (whichever is shorter) before the first dose of study drug
Prior treatment within the following timeframes:\r\n* Systemic chemotherapy or biologic therapy =<  weeks or  half lives (t /) of the agent used, whichever is shorter, prior to the start of neratinib \r\n* Radiation therapy outside the central nervous system days prior to neratinib \r\n* Radiation to the central nervous system =<  weeks prior to initiation of neratinib
Three weeks or  half-lives (whichever is shorter) from previous systemic anticancer therapy; at least  weeks from major surgery and recovered; at least  weeks from palliative radiation and recovered; no more than  mg/m^ cumulative dose of doxorubicin or equivalent anthracycline dose is allowed
At least  weeks beyond the last chemotherapy (or ?  half-lives for targeted agents, whichever is shorter), radiotherapy, major surgery or experimental treatment and recovered from all acute toxicities (? Grade )
At least  days from the last therapy dose or  half-lives (whichever is shorter), and resolution of toxicity related to the last therapy, excluding grade  or less peripheral neuropathy and alopecia; for radiation therapy, a minimum of  weeks and resolution of all acute toxicity will be required
any anti-cancer therapy including blinatumomab, chemotherapy, radiation therapy targeted small molecule agents or investigational agents within  days, or  half-lives, whichever is shorter
At least  weeks beyond the last chemotherapy (or ?  half-lives for targeted agents, whichever is shorter), radiotherapy, major surgery or experimental treatment and recovered from all acute toxicities (? Grade )
Patients who received the last administration of an anti-cancer therapy including, chemotherapy, immunotherapy/biologic therapy, targeted therapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) or within  half-lives, whichever is shorter, prior to entering the study
Patients must be recovered from the effects of any prior chemotherapy, radiotherapy or surgery (i.e., toxicity no worse than Grade ); for patients who have been on monoclonal antibody therapy, at least one half-life or  weeks (whichever is shorter) should have elapsed prior to the first scheduled day of dosing with PFK-.
Patients must be at least  weeks beyond their previous cytotoxic chemotherapy; patient must be at least  half-lives or  weeks, whichever is shorter, from their previous targeted or biologic therapy; in addition, patients must be at least  weeks beyond the last session of radiation therapy; local palliative radiation therapy that is not delivered to all target lesions is allowed immediately before or during treatment
Prior chemotherapy, targeted therapy or monoclonal antibody therapy within  weeks of start of study treatment (Day), or  half-lives, whichever is shorter.
Prior therapy:\r\n* Patients with recurrent, metastatic triple negative breast cancer must have had at least  chemotherapy regimen for metastatic breast cancer or have developed metastatic breast cancer within  year of completion of adjuvant chemotherapy\r\n* Prior therapy for high grade serous platinum-sensitive ovarian cancer patients must have included  prior platinum-based chemotherapy regimens\r\n* Participants must be at least  weeks since prior radiation therapy,  weeks since prior chemotherapy, and  weeks if the last regimen included carmustine (BCNU) or mitomycin C\r\n* No small-molecular kinase inhibitors or any other type of investigational agent within  weeks before the first dose of study treatment or  half-lives of the compound or active metabolite, whichever is shorter\r\n* For any hormonal therapy, participants must have stopped them at least  week prior to initiating therapy\r\n* Amount of prior radiotherapy: participants may not have had > % of their bone marrow radiated
Patients must have recovered from clinically significant toxicity of prior therapy to grade =<  or pre-treatment baseline; the following intervals from previous treatments are required prior to day  of study therapy:\r\n*  weeks from the completion of radiation for recurrent GBM unless there is surgical diagnosis of recurrence or a new lesion that was not previously radiated\r\n*  weeks from a nitrosourea chemotherapy\r\n*  weeks from a non-nitrosourea chemotherapy\r\n*  weeks from an investigational agent (not Food and Drug Administration [FDA] approved) (or  half lives, whichever is shorter)\r\n*  weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., erlotinib, hydroxychloroquine, etc.) (or  half lives, whichever is shorter)
Major surgery, chemotherapy, systemic therapy (excluding hydroxyurea, steroids, and any targeted small molecules or biologics), or radiotherapy, or biotherapy targeted therapies within  days or  half-lives (whichever is shorter) prior to Cycle , Day  treatment, except if approved by the Sponsor.
Chemotherapy, immunotherapy, biologic therapy, or any other anticancer therapy within  weeks (or five elimination half lives for noncytotoxics, whichever is shorter) of Day  of trial drug treatment ( weeks for nitrosureas or mitomycin). Subjects on therapy with trastuzumab (trastuzumab cohort) may continue with trastuzumab during the screening phase of the study. Subjects on endocrine therapy may continue with antihormonal therapy until Day  of the study.
Treatment with hormonal therapy (except hormone replacement therapy or oral contraceptives) or biologic therapy within  weeks or  half-lives, whichever is shorter, prior to initiation of study drug. This requirement may be waived at the investigator's request if the participant has recovered from therapeutic toxicity to the degree specified in the protocol, with approval of the Medical Monitor
Major surgery, chemotherapy, systemic therapy (excluding steroids hydroxyurea steroids, and any targeted small molecules or biologics), or radiotherapy, within  days or  half-lives (whichever is shorter) prior to Cycle , Day  treatment, except if approved by the Sponsor.
Within  weeks prior to the first dose of CDX- of any oral therapy or . half lives whichever is longer or following palliative radiation therapy. Concurrent use of hormones for non-cancer related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable.
Washout period prior to day  cycle :\r\n* >=  weeks since last chemotherapy or therapeutic radiation therapy\r\n* >=  weeks or  half-lives since prior antibody-based therapy, whichever is shorter\r\n* >=  weeks since any oral anti-neoplastic or oral investigational agent\r\n* Resolution of treatment-related toxicity to =< grade ; alopecia and cutaneous toxicity are allowed =< grade \r\n* >=  week since palliative radiotherapy (RT)
Patients should be off radiation therapy, chemotherapy, investigational agents, hormonal therapy, or immunotherapy for  weeks (or  half-lives of the therapy, whichever is longer) prior to first dose in the study, and off bevacizumab  weeks
Patient underwent major surgery within  weeks before the first dose of PBI  or received cancer-directed therapy (chemotherapy, radiotherapy, hormonal therapy, biologic or immunotherapy, etc.) or an investigational drug or device within  weeks ( weeks for mitomycin C, nitrosoureas, and liposomal doxorubicin) or  half-lives of that agent (whichever is shorter) before the first dose of PBI . (For agents in which the total of  half-lives is < days, there must be a minimum of  days between termination of the investigational drug and administration of PBI ). Note that prior liver-directed therapies will be permitted (i.e., chemoembolization, radioembolization), as long as target lesions in the liver have demonstrated growth after the liver-directed treatment. Any drug-related toxicity, with the exception of alopecia, should have recovered to ? Grade .
At least  weeks from previous cytotoxic chemotherapy or radiation therapy and at least  half-lives or  weeks, which ever is shorter, after targeted or biologic therapy
Participants may not have had other anti-neoplastic therapies within the following timelines:\r\n* Radiation within  weeks\r\n* Cytotoxic chemotherapy or monoclonal antibodies within  weeks, if all treatment-related toxicities have resolved to =< grade  prior to starting study treatment\r\n* EGFR tyrosine kinase inhibitor within  weeks\r\n* Any other small molecule inhibitor within  weeks or  half-lives of the compound, whichever is shorter\r\n* Experimental treatment of any type within  days
Any cancer-directed therapy (chemotherapy, radiotherapy, hormonal therapy, biologic or immunotherapy, etc.) within  days or  half-lives, whichever is shorter
Patient must have completed any prior cytotoxic chemotherapy or radiation therapy at least  days prior to starting the study drug(s), except selective RAF inhibitors (vemurafenib, dabrafenib or LGX); there is no washout period for prior selective RAF inhibitors; patients must be at least  half-lives or  weeks, whichever is shorter, from their previous targeted or biologic therapy; local palliative radiation therapy that is not delivered to all target lesions is allowed immediately before or during treatment
Patients must be at least  weeks past receiving cytotoxic therapy and at least  half-lives after their previous treatment or  weeks, whichever is shorter, after biologic therapy; patients may receive palliative radiotherapy immediately or during treatment provided that not all target lesions are radiated
Patient must be at least  weeks or five half-lives (whichever is shorter) from last standard or experimental therapy, except:\r\n* Patients who have received prior pazopanib are eligible but must not have received it in the last two weeks
Patients must be off prior cytotoxic chemotherapy for at least three weeks; for biologic or targeted therapy, there should be five half lives or three weeks, whichever is shorter, between their last treatment and the first dose on this trial
Receipt of any chemotherapy or small molecule targeted therapy (such as imatinib or other tyrosine kinase inhibitors, and including any experimental therapies) or radiation therapy within  days or  half-lives, whichever is shorter, prior to the first dose of MEDI-
Cancer-directed therapy (chemotherapy, radiotherapy, hormonal therapy with the exception of LHRH agonists for prostate cancer, biologic or immunotherapy, etc.) within  days of the first dose of study drug or  half-lives, whichever is shorter. Palliative radiotherapy is allowed prior to initiating treatment if associated toxicity resolved to ? Grade .
At least  days or  half-lives, whichever is shorter, from the completion of anti-cancer treatment (including, but not limited to, immunotherapy, chemotherapy, targeted therapy and biologic therapy) to the start of study treatment, excluding ibrutinib where the window may be less and at minimum  days (modified by amendment )
Treatment with any anti-cancer therapy, including radiotherapy, chemotherapy, biologic therapy, or herbal therapy within  weeks or  half-lives (for systemic agents), whichever is shorter
Have discontinued all previous cancer therapies and any agents that have not received regulatory approval for any indication, for at least  days or  halflives prior to study enrollment, whichever is shorter, and recovered from the acute effects for therapy.
Chemotherapy, hormonal therapy or radiation therapy within the past  weeks, antibody/biologic therapy within  half-lives or within the past  weeks (whichever is longer)
An interval shorter than  days from the last dose of chemotherapy or HER-directed\n             therapy until the time of randomization
Washout from any prior biologic or targeted therapy at least  weeks or five times the T/ (whichever is shorter) prior to CD
Treatment with any anti-cancer therapy, including radiotherapy, chemotherapy, biologic therapy, or herbal therapy within  weeks or  half-lives (for systemic agents) whichever is shorter
Treatment with any anti-cancer therapy, including radiotherapy, chemotherapy, biologic therapy, or herbal therapy within  weeks or  half-lives (for systemic agents), whichever is shorter
Any anti-cancer therapy or treatment incorporating chemotherapy, immunotherapy, hormonal therapy, or biologic therapy within  days of the start of trial treatment or within  times the half life of such treatment, whichever is shorter. Treatment with nitrosoureas or mitomycin C are exceptions to this for which a treatment interval of at least  weeks is required
The subject must not have received anti-tumor radiotherapy, biologic therapy, chemotherapy, or immunotherapy within  days or  half lives (whichever is shorter) of the start of Day . The subject must not have received hormonal therapy for anti-tumor purposes within  week prior to the start of Cycle  Day .
Surgery or radiation therapy within  weeks; cytotoxic anti-cancer therapy within  weeks; non-cytotoxic anti-cancer therapy within  weeks, or  half-lives (whichever is shorter) of study day 
Patients may not have had prior chemotherapy, radiotherapy, hormonal therapy, or biologic therapy in the  weeks prior to study entry with the exception of mitomycin C or nitrosoureas, for which patients must be  weeks from prior treatment. For patients who have been treated with targeted therapy,  half-lives of that therapy (or  days, whichever is shorter) must have passed prior to enrollment in the study.
Chemo-, immune-, or hormone-therapy within  elimination half life times or  weeks prior to randomization, whichever is the shorter. Radiotherapy (including pre- or post-operative brachytherapy) within  weeks prior to randomization.
Prior to the first dose of study treatment, patients who have received systemic antineoplastic therapy or any investigational therapy within  weeks or within  half- lives of the therapy prior to starting study treatment, whichever is shorter, or for cyclical therapy, within one cycle length (e.g.  weeks for nitrosourea, mitomycin-C).
Prior radiation therapy, chemotherapy, hormonal therapy, or immunotherapy within  weeks prior to screening or  half-lives of the therapy, whichever is shorter
Patients must be at least  weeks after cytotoxic therapy and at least  half-lives after their previous treatment or  weeks, whichever shorter, after biologic therapy; patients may receive palliative radiotherapy immediately before or during treatment provided that not all target lesions are radiated
RCC patients only: Having received chemotherapy prior to study entry within  half-lives of the agent (as described in the package insert), or  weeks prior to registration (whichever is shorter) with resolution of side effects from therapy to =< grade 
Prior therapy with sorafenib or other VEGF- tyrosine kinase inhibitors within  days or  half lives (whichever is shorter); patients are allowed to have been on prior bevacizumab therapy as long as it was stopped at least - weeks prior to enrolling on this trial; prior erlotinib is also allowed
Prior anti-cancer therapy (e.g., chemotherapy, biologic therapy, radiotherapy, or hormonal therapy) within  weeks or  half-lives (whichever is shorter) of the first dose of study treatment
Requires any concomitant antineoplastic therapy. Prior chemotherapy should not be administered within  half-lives or  days whichever is shorter. Subjects on a current stable dose of hormonal treatments may continue on a stable dose during the study (i.e. arimidex, amarosin, herceptin).
Major surgery within  weeks or till recovery to baseline functioning (per patient) whichever is shorter
Prior radiation therapy or chemotherapy within  weeks prior to study radiotracer administration (washout is one half-life of the drug or  weeks, whichever is longest)
Subject has received any of the following within  days or  drug half-lives (whichever is shortest) prior to the first dose of chemotherapy, or has not recovered to less than grade  clinically significant adverse effect(s)/toxicity(s) of the previous therapy\r\n* Any anti-cancer therapy including chemotherapy, biologic agents for antineoplastic treatment (e.g. monoclonal antibodies) or radiotherapy, investigational therapy, including targeted small molecule agents
Patients may not have had prior chemotherapy or biologic therapy in the  weeks prior to study entry; for patients who have been treated with targeted therapy,  half-lives of that therapy (or  days, whichever is shorter) must have passed prior to enrollment in the study
Patients must have completed any chemotherapy, radiation therapy, surgery, or biologic therapy >=  weeks (or >=  half-lives, whichever is shorter) prior to entering the study; patients must be >=  weeks since any prior administration of a study drug in an exploratory investigational new drug (IND)/phase  study and >=  week since any palliative radiation therapy; patients must have recovered to eligibility levels from prior toxicity or adverse events
Major surgery, chemotherapy, systemic therapy (excluding hydroxyurea,steroids and any targeted small molecules or biologics), or radiotherapy, within  days or  half-lives (whichever is shorter) prior to the Cycle , Day  treatment, except if approved by the Sponsor.